Healthcare Stocks

U.S. FDA says India-made eye drop linked to some infections, blindness and one death

  • February 03, 2023 07:43 AM PST | Reuters
 U.S. FDA says India-made eye drop linked to some infections, blindness and one death

NEW DELHI (Reuters) - The U.S. Food and Drug Administration has warned against using an India-made eye drop that has been linked to the outbreak of a drug-resistant bacteria leading to adverse events

Read More...
Know Labs Provides Update On Strategic Partners

Know Labs Provides Update On Strategic Partners

  • February 02, 2023 06:46 AM PST | Reuters

Feb 2 (Reuters) - Know Labs Inc: * KNOW LABS PROVIDES UPDATE ON STRATEGIC PARTNERS ENGAGED IN DATA SCIENCE, PRODUCT ENGINEERING AND REGULATORY AFFAIRS TO ACCELERATE PROGRESS TOWARD FDA APPLICATION

Read More...
Artelo Biosciences Completes Enrollment Of The Phase 1B Stage Of Its Cares Clinical Trial

Artelo Biosciences Completes Enrollment Of The Phase 1B Stage Of Its Cares Clinical Trial

  • February 02, 2023 06:41 AM PST | Reuters

Feb 2 (Reuters) - Artelo Biosciences Inc: * ARTELO BIOSCIENCES COMPLETES ENROLLMENT OF THE PHASE 1B STAGE OF ITS CARES CLINICAL TRIAL EVALUATING ART27.13 FOR THE TREATMENT OF CANCER-RELATED ANOREXIA

Read More...
2Seventy Bio Announces $94 Million In U.S. Revenue For Abecma In Q4

2Seventy Bio Announces $94 Million In U.S. Revenue For Abecma In Q4

  • February 02, 2023 06:39 AM PST | Reuters

Feb 2 (Reuters) - 2Seventy Bio Inc: * 2SEVENTY BIO - ON FEB 2, CO ANNOUNCED ABECMA GENERATED ABOUT $94 MILLION IN U.S. REVENUE DURING Q4 & ABOUT $297 MILLION IN U.S. REVENUE DURING YEAR ENDED DEC 31,

Read More...
Unicycive Enters Into Licensing Agreement With Lotus For Renazorb In Korea

Unicycive Enters Into Licensing Agreement With Lotus For Renazorb In Korea

  • February 02, 2023 06:38 AM PST | Reuters

Feb 2 (Reuters) - Unicycive Therapeutics Inc: * UNICYCIVE ANNOUNCES EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT WITH LOTUS FOR RENAZORB IN REPUBLIC OF KOREA * UNICYCIVE THERAPEUTICS INC - AGREEMENT

Read More...
Unicycive Announces Exclusive License, Development Agreement With Lotus

Unicycive Announces Exclusive License, Development Agreement With Lotus

  • February 02, 2023 06:38 AM PST | Reuters

Feb 2 (Reuters) - Unicycive Therapeutics Inc: * UNICYCIVE ANNOUNCES EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT WITH LOTUS FOR RENAZORB IN REPUBLIC OF KOREA * UNICYCIVE THERAPEUTICS INC - AGREEMENT

Read More...
Bio-Techne Corp reports results for the quarter ended in December - Earnings Summary

Bio-Techne Corp reports results for the quarter ended in December - Earnings Summary

  • February 02, 2023 06:33 AM PST | Reuters

* Bio-Techne Corp reported quarterly adjusted earnings of 47 cents​​ per share for the quarter ended in December. The mean expectation of twelve analysts for the quarter was for earnings of 62 cents

Read More...
IRadimed Corp <IRMD.O>: Profits of 32  cents announced for fourth quarter

IRadimed Corp <IRMD.O>: Profits of 32  cents announced for fourth quarter

  • February 02, 2023 06:33 AM PST | Reuters

2 February 2023 02:32 p.m. ​All figures in US dollars. The profits announced by IRadimed Corp in the fourth quarter were higher than the Refinitiv mean estimate of profits. The company reported

Read More...
IRadimed Corp reports results for the quarter ended in December - Earnings Summary

IRadimed Corp reports results for the quarter ended in December - Earnings Summary

  • February 02, 2023 06:33 AM PST | Reuters

* IRadimed Corp reported quarterly adjusted earnings of 32 cents​​ per share for the quarter ended in December. The mean expectation of two analysts for the quarter was for earnings of 30 cents per

Read More...
Bio-Techne Corp <TECH.O>: Profits of 47  cents announced for second quarter

Bio-Techne Corp <TECH.O>: Profits of 47  cents announced for second quarter

  • February 02, 2023 06:32 AM PST | Reuters

2 February 2023 02:32 p.m. ​All figures in US dollars. The profits announced by Bio-Techne Corp in the second quarter were lower than the Refinitiv mean estimate of profits. The company reported

Read More...
Eli Lilly and Co <LLY>: Profits of $2.09 announced for fourth quarter

Eli Lilly and Co <LLY>: Profits of $2.09 announced for fourth quarter

  • February 02, 2023 06:32 AM PST | Reuters

2 February 2023 02:31 p.m. ​All figures in US dollars. The profits announced by Eli Lilly and Co in the fourth quarter were higher than the Refinitiv mean estimate of profits. The company reported

Read More...

Frequently Asked Questions

Healthcare stocks are companies involved in the healthcare industry. These companies are engaged in manufacturing. Various pharmaceutical products, including medicine, medical devices, medical care through hospitals and medical centres, health insurance, etc. Despite stock market risks, healthcare stocks can provide substantial returns in the long run. The healthcare sector has been one of the top-performing sectors over the past year. The covid-19 pandemic has accelerated its growth. Some of the top healthcare stocks include Walgreens Boots Alliance Inc. (WBA), Sage Therapeutics Inc. (SAGE), Bio-Rad Laboratories Inc. (BIO), Pfizer Inc, Moderna Inc, etc.

The healthcare sector is one of the largest and most complex sectors in the US, which is comprised of various companies that engage in a wide range of healthcare-related operations. Some of the top healthcare stocks in the US are as follows: UnitedHealth Group Inc. (UNH) Johnson & Johnson (JNJ) Pfizer Inc (PFE) Abbvie Inc (ABBV) Eli Lilly and Co (LLY)

The healthcare sector is one of the centers of attraction of investors in recent days, especially considering the growth potentials of the companies. Some of the best US healthcare stocks are as follows, that maintained has maintained a steady momentum even amid the market downturn. Johnson & Johnson (JNJ) Abbvie Inc (ABBV) Eli Lilly and Co (LLY) Merck & Co Inc (MRK) Bristol-Myers Squibb Co (BMY)

AI healthcare stocks are companies that use artificial intelligence to provide tailor-made products and services to the healthcare industry. The innovation in AI healthcare companies is rapidly transforming the industry. Their help to understand and classify clinical documentation, clinical notes on patients, and insight into methods for better results.